194 patents
Page 8 of 10
Utility
Genetically Engineered T Cells Having Improved Persistence In Culture
18 Mar 21
A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Hanspeter Waldner
Filed: 4 Sep 20
Utility
Methods and Compositions of Cytotoxic T Cell Depletion
11 Mar 21
The present application relates to compositions and methods for controlled cytotoxic T cell depletion, such as for the treatment of various diseases and conditions associated with cytotoxic T cells.
Basha STANKOVICH
Filed: 26 Apr 19
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
ALIREZA REZANIA, REBECA RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Methods and Compositions for Treating Cancer
4 Mar 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 10 May 19
Utility
Novel Rna-programmable Endonuclease Systems and Uses Thereof
25 Feb 21
Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs).
Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Michael Biag GAMALINDA, Ashish GUPTA, Christian PITZLER, Florian RICHTER, Jan TEBBE, Christopher CHENG, Ryo TAKEUCHI, Caroline W. REISS
Filed: 19 Mar 19
Utility
Self-inactivating (Sin) Crispr/cas or CRISPR/CPF1 Systems and Uses Thereof
4 Feb 21
The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems.
Seshidhar Reddy POLICE, Song CHOU, Thomas James CRADICK, Robert NG
Filed: 9 Nov 18
Utility
Methods and Compositions for Improved Homology Directed Repair
14 Jan 21
The disclosure features methods of increasing repair of a DNA double stranded break (DSB) in a target gene by the homology-directed repair (HDR) pathway.
Sanjay D'Souza, Jason West
Filed: 17 Jun 20
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
4 Jan 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 6 Jun 19
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
30 Dec 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 28 Jul 20
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
30 Dec 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 2 Aug 20
Utility
Materials and Methods for Controlling Gene Editing
30 Dec 20
The present application provides materials and methods for controlling gene editing.
Ryo TAKEUCHI, Abraham SCARIA
Filed: 25 Jun 20
Utility
Universal donor cells
14 Dec 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 13 Jul 20
Utility
Materials and Methods for Treatment of Autosomal Dominant Cone-rod Dystrophy
9 Dec 20
The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell.
Ryo TAKEUCHI, Akiko NOMA, Shuying HE, Abraham SCARIA
Filed: 11 Jun 20
Utility
Gene Editing for Hemophilia a with Improved Factor VIII Expression
9 Dec 20
Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo.
Alan Richard Brooks
Filed: 14 Apr 20
Utility
Novel Rna-programmable Endonuclease Systems and Their Use In Genome Editing and Other Applications
9 Dec 20
Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Ashish GUPTA, Jan TEBBE, Cindy SCHULENBURG, Christian PITZLER, Michael Biag GAMALINDA, Sabine JACH, Florian RICHTER, Anup ARUMUGHAN, Corinna SAALWÄCHTER
Filed: 13 Dec 18
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
7 Dec 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 5 Jun 19